The greatest advances have been seen in low grade glioma, a largely single-pathway disease and currently the only pediatric CNS tumor with FDA-approved targeted therapies – dabrafenib/trametinib for upfront treatment of BRAF V600E mutant LGG and tovorafenib for BRAF-altered LGG in the recurrent setting. This evidence concerns the gene BRAF and central nervous system neoplasm.